The data show that fleas collected from around the globe continue to be as highly susceptible to imidacloprid today as they were when the monitoring commenced. In 2009, the FSM program celebrates its 10th year.
Since 2001, when the diagnostic dose was established enabling field monitoring to begin, 1356 samples have been submitted, 1014 samples have been analyzed and 13 flea isolates identified for more detailed laboratory investigation. After additional testing none of those isolates were considered to have reduced susceptibility.
The ongoing monitoring through the innovative FSM program confirms that veterinarians and pet owners can continue to trust in imidacloprid, the active ingredient in Bayer Animal Health's Advantage® Topical Solution and K9 Advantix®.
The Bayer Animal Health-funded FSM program is the first and only initiative of its kind in the field of companion animal parasites and includes a group of internationally renowned, independent researchers who work together with Bayer Animal Health to continuously monitor the susceptibility of fleas to imidacloprid. Under the international program, data is collected from the United States, Germany, France and the UK. In the US alone, there are over 100 clinics across 23 states involved in the collection of field isolates which are then sent to independent laboratories in California and Alabama for testing.
"The inception in 1999 of the global monitoring program for susceptibility of fleas to imidacloprid was a significant milestone in resistance surveillance and risk assessment. That this program has now reached its tenth anniversary testifies to the strength and motivation of the international team conducting the research, and the commitment of Bayer to ensure that its products continue to provide proven, efficient, reliable flea control", said Dr. Michael Rust, Professor of Entomology, College of Natural and Agricultural Sciences, University of California, Riverside.
The methodology utilized by the FSM follows a three-step approach. Flea egg samples are collected by participating veterinarians from infested animals and sent to the monitoring laboratories for testing. Twenty eggs are reared on media containing 3 ppm imidacloprid (the diagnostic dose) and 20 in media without imidacloprid (controls). Adult emergence is measured and if >5%, that population of fleas is maintained to allow further laboratory evaluation of susceptibility. The third evaluation step is to investigate the susceptibility of the flea population when placed on dogs and treated with Advantage®. To date, no isolates have survived the second stage of the testing process, proving the long-standing efficacy of imidacloprid in killing fleas.
"Ten years after the initiation of the Flea Susceptibility Monitoring program, our efforts remain a unique and important strategy for assessing the continuing efficacy of imidacloprid against fleas. Monitoring the performance of current agents like imidacloprid is necessary to help maintain a longer, viable product life for these products", said Dr. Bryon Blagburn, Distinguished University Professor, College of Veterinary Medicine, Auburn University, USA.
"Bayer Animal Health is committed to remaining at the forefront of understanding parasitology and its related diseases, and, in this way, providing effective treatments that continue to ensure optimal animal health," said Sarah Weston, Global Veterinary Services Manager, Bayer Animal Health.
About the Flea Susceptibility Monitoring program
The FSM is a large-scale international program based on a monitoring methodology which utilizes flea eggs collected from the field in the US, Germany, UK and France (Australia will be included from this year). Egg collection is carried out by a network of veterinarians and the samples analyzed in four investigating laboratories based in three countries. The FSM has run for 10 years and, to date, has not detected any reduced susceptibility to imidacloprid. A dedicated team of 15 people including independent experts in veterinary parasitology, entomology and molecular biology in addition to Bayer staff work together to manage the FSM program.
About Bayer HealthCare
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading innovative companies in the health care and medical products industry. The company combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The company's pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide.
With sales of EUR 956 million (2007), the Animal Health Division is one of the world's leading manufacturers of veterinary drugs. The division produces and markets more than 100 different veterinary drugs and care products for livestock and companion animals.
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our annual and interim reports to the Frankfurt Stock Exchange and in our reports filed with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to confirm them to future events or developments.
Bayer, the Bayer Cross, K9 Advantix and Advantage are registered trademarks of Bayer.
Press Contact:Bayer Animal Health
Bob Walker | EurekAlert!
Further reports about: > Animal > Animal Health Division > FSM > Health > Healthcare > Molecular Biology > Monitoring > Veterinary > animal parasites > effective treatment > imidacloprid in killing fleas > optimal animal health > susceptibility > testing process > veterinary drugs > veterinary parasitology
Atomic-level motion may drive bacteria's ability to evade immune system defenses
24.04.2017 | Indiana University
Two-dimensional melting of hard spheres experimentally unravelled after 60 years
24.04.2017 | University of Oxford
More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.
Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...
Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.
"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...
The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.
Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...
The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...
Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.
Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...
20.04.2017 | Event News
18.04.2017 | Event News
03.04.2017 | Event News
24.04.2017 | Physics and Astronomy
24.04.2017 | Materials Sciences
24.04.2017 | Life Sciences